From sensing outbreaks to innovative cures, do more with AI
The pharmaceuticals and life sciences sector is in the throes of change. The rise of specialty drugs catering to smaller patient populations has complicated both clinical trials and regulatory approvals. As already long research and development timelines extend further, it will stretch the capacity of pharmaceuticals companies to launch new drugs. Amidst tough conditions, the search for efficiency, agility and efficacy in bringing products to market is assuming greater urgency. That quest is driving adoption of Artificial Intelligence (AI) and automation in the industry. The decision to deploy AI is driven equally by the need to acquire competitive advantage and a push from the executive leadership. But there are ethical issues to tackle as well.
Download our exclusive report to find out how the pharmaceuticals and life sciences industry is getting ready with the AI advantage.
